M. Giaffer

发表

The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique.

C. Holdsworth, B. Duerden, M. Giaffer, 1991, Journal of medical microbiology.

A double‐blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis

J. Mansfield, P. Cann, C. Holdsworth, 2002, Alimentary pharmacology & therapeutics.

99Tcm HMPAO-labelled leucocyte imaging in Crohn's disease: a subtraction technique for the quantification of disease activity.

W. Tindale, C. Holdsworth, D. Barber, 1992, Clinical physics and physiological measurement : an official journal of the Hospital Physicists' Association, Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations for Medical Physics.

Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

N. Talley, D. Armstrong, K. Bardhan, 2002, European journal of gastroenterology & hepatology.

Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease.

J. Mansfield, C. Holdsworth, M. Giaffer, 1995, Gut.

Crohn's disease of late onset in Blackpool.

M. Giaffer, F. I. Lee, 1987, Postgraduate medical journal.

Labelled leucocyte scintigraphy in inflammatory bowel disease: clinical applications.

M. Giaffer, 1996, Gut.

Background subtraction: a new approach to the assessment of disease activity in Crohn's disease using 99mTc-HMPAO-labelled leucocytes.

W. Tindale, C. Holdsworth, M. Giaffer, 1994, Scandinavian journal of gastroenterology. Supplement.

Quantification of disease activity in Crohn's disease by computer analysis of Tc-99m hexamethyl propylene amine oxime (HMPAO) labelled leucocyte images.

W. Tindale, C. Holdsworth, D. Barber, 1993, Gut.

Long‐term effects of elemental and exclusion diets for Crohn's disease

P. Cann, C. Holdsworth, M. Giaffer, 1991, Alimentary pharmacology & therapeutics.

Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day

J. H. Baron, J. Lennard-jones, P. Mcintyre, 1992, Alimentary pharmacology & therapeutics.

of active ulcerative colitis . propionate v prednisolone in the treatment Double blind trial of oral fluticasone

C. Holdsworth, C. Record, D. Burke, 2006 .

Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis.

C. Holdsworth, C. Record, D. Burke, 1993, Gut.

Elemental diet in steroid-dependent and steroid-refractory Crohn's disease.

P. Cann, C. Holdsworth, M. Giaffer, 1991, The American journal of gastroenterology.

Clinical tolerance to three 5‐aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine

C. Holdsworth, M. Giaffer, C. O'Brien, 1992, Alimentary pharmacology & therapeutics.

Drug-induced oesophageal ulceration in a patient with acquired immunodeficiency syndrome

M. Giaffer, J. Craig, M. Talbot, 1996, International journal of STD & AIDS.

Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease

C. Holdsworth, M. Giaffer, G. North, 1990, The Lancet.

Value of technetium-99m HMPAO-labelled leucocyte scintigraphy as an initial screening test in patients suspected of having inflammatory bowel disease

W. Tindale, M. Giaffer, D. Holdsworth, 1996, European journal of gastroenterology & hepatology.

Quantitative assessment of overall inflammatory bowel disease activity using labelled leucocytes: a direct comparison between indium-111 and technetium-99m HMPAO methods.

J. Mansfield, W. Tindale, C. Holdsworth, 1995, Gut.

Maintenance of Crohn’s disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules

S. Travis, J. Green, M. Giaffer, 2001, Alimentary pharmacology & therapeutics.

Antibodies to Saccharomyces cerevisiae in patients with Crohn's disease and their possible pathogenic importance.

C. Holdsworth, M. Giaffer, A. Clark, 1992, Gut.

Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease.

C. Holdsworth, B I Duerden, B. Duerden, 1992, Gut.

Effects on an elemental diet on the faecal flora in patients with Crohn's disease

C. Holdsworth, B. Duerden, M. Giaffer, 1991 .

Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial.

D. Gleeson, J. Underwood, D. Triger, 1999, Gastroenterology.

disease . acid diet in treatment of active Crohn ' s Controlled trial of oligopeptide versus amino

J. Mansfield, C. Holdsworth, M. Giaffer, 2006 .

Double blind trial oforal fluticasone propionate v prednisolone inthetreatmentofactive ulcerative colitis

D. Burke, C. Hawkey, M. Keech, 1993 .

Challenges and Controversies in the Management of Hepatitis C Virus Infection (Part 1)

M. Giaffer, N. B. Haj, N. Haj, 2005 .

Helicobacter pylori Eradication in Patients on Long‐ Term H2 Receptor Antagonists. Economic and Symptomatic Benefits. A Large Prospective Study in Primary Care

M. Giaffer, S. Verma, 2002, Helicobacter.

Open-access versus hospital-initiated flexible sigmoidoscopy: a comparative audit of efficacy

M. Giaffer, S. Verma, Mustafa H. Giaffer, 2001, European journal of gastroenterology & hepatology.